Lack of Professionalism in KT&G's Board of Directors

Business by 2FIRSTS.ai
Jan.23.2024
Lack of Professionalism in KT&G's Board of Directors
According to a report by South Korean Economic Daily, there is a lack of expertise among external directors at KT&G, as many are not industry professionals and have failed to address major issues.

According to a recent report from the Korean Economic Daily, the board of directors of Philip Morris International (PMI) consists of 11 external directors, all of whom are current senior executives at global companies. On the other hand, among the six external directors of KT&G, the Korean Tobacco company, only the representative director from SK Materials and the current chairman, Ren Min-kyu, are senior executives at a large corporation.

 

KT&G's external directors include chairs of industry associations unrelated to the company, representatives of small entertainment companies and advertising agencies. One of the members is even the president of an advertising agency with less than 10 employees. However, KT&G is unable to legally engage in advertising activities.

 

One prominent issue is the lack of professionalism among the external directors of KT&G. According to a survey by the Korean Economic News, out of the 44 external directors who have served or have previously served at KT&G since its privatization in 2001, the majority, 17 individuals, were professors, while only 12 were entrepreneurs. In contrast, the proportion of corporate executives at Philip Morris International is noticeably higher.

 

Due to a lack of expertise, the board of directors at KT&G failed to provide advance warning on several significant issues, such as the recent controversial "crisis of unrecoverable deposits in the US.

 

Industry insiders stated that during the KT&G board meeting in December 2021, a proposal concerning the suspension of sales of products by its US subsidiary was brought up. Surprisingly, none of the external directors at the time pointed out the potential risk of not being able to refund deposits.

 

In addition, external directors have not raised concerns about KT&G's establishment of a management system predominantly composed of executives with a background in civil service. It is understood that since 2001, KT&G has distributed approximately 11 million KT&G shares and around 100 billion yuan in cash to various funds and stock associations consisting of current and former employees, transferring ownership without charge, thereby becoming the largest shareholder (based on common stock, accounting for 9.6%).

 

In this situation, appointing external directors is equivalent to handing over voting rights to the company, significantly impacting the "government official-turned-CEO" model.

 

Critics in the industry have condemned KT&G for appointing non-experts as external directors, essentially demanding that they serve as mere "solicitors" who are expected to vote in favor of the company's proposed agenda.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai
Editorial says West Virginia’s HB 5437 “Vape Safety Act” goes too far, targeting residency and citizenship provisions
Editorial says West Virginia’s HB 5437 “Vape Safety Act” goes too far, targeting residency and citizenship provisions
A News and Sentinel editorial argues that West Virginia’s HB 5437, the “Vape Safety Act,” goes beyond reasonable regulation by adding provisions barring any part of a vape or smoke shop from being used as a residence and requiring owners to be U.S. citizens.
Feb.27 by 2FIRSTS.ai
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G said it plans to cancel all treasury shares it holds, totaling 10,866,189 shares, representing about 9.5% of shares outstanding, in line with Korea’s third amendment to the Commercial Act requiring companies to cancel repurchased shares within one year. The company also disclosed progress on its shareholder-return plan and multiple agenda items for next month’s shareholders meeting.
Feb.26
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
Special Report|FDA Revises Device Name in Glas Vape Authorization; Company Signals Optimism on Menthol, Flavored Pods
The FDA updated public records on the PMTA authorization of a Glas vape product, renaming “Glas G Device” to “Glas G² Device” and releasing the order letter detailing scientific review and marketing restrictions. Company disclosures suggest the platform may include age-verification technology. If confirmed, Glas G² could be the first vape with device-level age verification to receive an FDA MGO. Glas executives also said menthol and other flavored pods could gain authorization in the future.
Special Report
Mar.14
Azerbaijan Cancels E-Cigarette State Standard as Full Vape Ban Takes Effect on April 1
Azerbaijan Cancels E-Cigarette State Standard as Full Vape Ban Takes Effect on April 1
The Azerbaijan Institute of Standardization (AZSTAND) has announced the cancellation of state standard AZS 941:2023, “Electronic Cigarettes. General Technical Specifications.”Under legal amendments adopted on December 30, 2025, Azerbaijan has prohibited from April 1, 2026 the import, export, manufacture, storage, wholesale and retail sale, and use of e-cigarettes and their components.
Apr.07 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24